Company Overview
Snapshot
Founded in May 2017 by Dr. Shulamit Richter Dayan, Dermafence operates with 1–10 employees. The company has secured $20,000 in total funding across three rounds from one investor. In March 2018, Dermafence received a grant from the Israel Innovation Authority.
Business overview
Dermafence is a Health Tech & Life Sciences company focused on developing proprietary technology for burn treatment. The company's core technology utilizes a GRAS formulation with a novel mechanism of action designed to prevent energy from penetrating deeper skin layers. Dermafence has developed a first-aid burn formulation that aims to restore and protect epidermal skin barrier function following exposure to insults that introduce energy to the skin, serving the medical technologies market.
Log in to access full profile ›Company Intelligence Q&A
- What is Dermafence's primary focus?
- Dermafence specializes in burn treatment technology, developing a proprietary GRAS formulation designed to prevent energy from progressing to deeper skin layers after burn exposure.
- When was Dermafence founded and by whom?
- Dermafence was founded in May 2017 by Dr. Shulamit Richter Dayan.
- Has Dermafence received any grants?
- Yes, Dermafence received a grant from the Israel Innovation Authority in March 2018. The company also received a grant from the Israel Innovation Authority in January 2017.
- What is Dermafence's current product stage?
- Dermafence's product is currently in the Research & Development (R&D) stage, focusing on developing its proprietary burn treatment technology.
- Which markets does Dermafence target?
- Dermafence targets the United States and Israel as its primary geomarkets.